Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 27,772 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo and sham treatment Clear all
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

NCT01714817
View directory record Official record
Conditions
Lupus Nephritis
Interventions
BMS-188667, Mycophenolate mofetil, Prednisone, Placebo matching with BMS-188667
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
26
States / cities
Birmingham, Alabama • Long Beach, California • San Leandro, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 19, 2026, 4:23 PM EDT
Completed Phase 2 Interventional Results available

Resveratrol and Exercise to Treat Functional Limitations in Late Life

NCT02523274
View directory record Official record
Conditions
Aging
Interventions
Resveratrol, Placebo, Exercise
Drug · Behavioral
Lead sponsor
University of Florida
Other
Eligibility
65 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Oct 19, 2026, 4:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects

NCT04809818
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
LT3001 drug product, Placebo, Aspirin, Clopidogrel, Apixaban, Dabigatran
Drug
Lead sponsor
Lumosa Therapeutics Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 19, 2026, 4:23 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome

NCT03325010
View directory record Official record
Conditions
Tourette Syndrome
Interventions
Valbenazine, Placebo oral capsule
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
6 Years to 17 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
34
States / cities
Sun City, Arizona • Rogers, Arkansas • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 19, 2026, 4:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Cow/Human Parainfluenza Virus Vaccine (rB/HPIV3) in Healthy Infants, Children, and Adults

NCT00366782
View directory record Official record
Conditions
Paramyxoviridae Infections, Virus Diseases
Interventions
rB/HPIV3, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 49 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 1, 2012 · Synced Oct 19, 2026, 4:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Trial Examining the Treatment of Common Warts With Combination Liquid Nitrogen (LN2) and Cantharidin

NCT01084824
View directory record Official record
Conditions
Verruca Vulgaris
Interventions
Liquid nitrogen and cantharidin, Liquid nitrogen and topical placebo
Drug
Lead sponsor
North Idaho Dermatology
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Coeur d'Alene, Idaho
Source: ClinicalTrials.gov public record
Updated Mar 11, 2010 · Synced Oct 19, 2026, 4:23 PM EDT
Completed Not applicable Interventional

The Effect of NADPH Oxidase and Creatine Supplementation on Microvascular Blood Flow Regulation

NCT06018480
View directory record Official record
Conditions
Endothelial Dysfunction
Interventions
Creatine Monohydrate, Maltodextrin (Placebo)
Other
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 19, 2026, 4:23 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Zoledronic Acid in Acute Spinal Cord Injury: Prevention of Bone Loss

NCT00844480
View directory record Official record
Conditions
Bone Loss
Interventions
zoledronic acid, placebo
Drug
Lead sponsor
Thomas J. Schnitzer
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 19, 2026, 4:23 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Vimseltinib for Tenosynovial Giant Cell Tumor

NCT05059262
View directory record Official record
Conditions
Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Diffuse, Tenosynovial Giant Cell Tumor, Localized
Interventions
Vimseltinib, Placebo
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
11
States / cities
Duarte, California • Sacramento, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 19, 2026, 4:23 PM EDT
Recruiting Phase 3 Interventional

A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)

NCT06568627
View directory record Official record
Conditions
Venous Leg Ulcer (VLU)
Interventions
EscharEx (EX-03), Placebo (Gel vehicle)
Drug
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Phoenix, Arizona • Fresno, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 19, 2026, 4:23 PM EDT
Completed Not applicable Interventional Results available

Dietary Nitrate Supplementation and Thermoregulation

NCT03506646
View directory record Official record
Conditions
Peripheral Arterial Disease, Peripheral Artery Disease
Interventions
Placebo, Beet root juice
Dietary Supplement
Lead sponsor
University of Nebraska
Other
Eligibility
50 Years to 85 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 19, 2026, 4:23 PM EDT
Completed Phase 2 Interventional Results available

A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction

NCT02742103
View directory record Official record
Conditions
Acute Myocardial Infarction, Moderate Renal Impairment
Interventions
CSL_112, Placebo
Biological · Other
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
13
States / cities
Birmingham, Alabama • Huntsville, Alabama • Concord, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 19, 2026, 4:23 PM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine

NCT01430442
View directory record Official record
Conditions
Migraine, Acute Treatment of Migraine
Interventions
Rimegepant, Placebo, Sumatriptan
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,026 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
41
States / cities
Scottsdale, Arizona • Tempe, Arizona • San Francisco, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 19, 2026, 4:23 PM EDT
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm A (Ivermectin 400)

NCT05736861
View directory record Official record
Conditions
Covid19
Interventions
Ivermectin, Placebo
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
87
States / cities
Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 19, 2026, 4:23 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis

NCT03025542
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Bexley, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 19, 2026, 4:23 PM EDT
Terminated Phase 2 Interventional Results available

Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial

NCT00675025
View directory record Official record
Conditions
Down Syndrome
Interventions
Donepezil hydrochloride (Aricept)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
31
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Oct 19, 2026, 4:23 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD

NCT03062540
View directory record Official record
Conditions
PTSD
Interventions
TNX-102 SL, Placebo SL Tablet
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
44
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 19, 2026, 4:23 PM EDT
Recruiting Phase 2 Interventional

Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis

NCT04380740
View directory record Official record
Conditions
Graft Vs Host Disease
Interventions
Placebo, Abatacept
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
15
States / cities
Duarte, California • Tampa, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 19, 2026, 4:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Magnesium and Vitamin D Supplementation and Cardiometabolic Outcomes

NCT03134417
View directory record Official record
Conditions
Overweight and Obesity, Vitamin D Deficiency, Magnesium Deficiency, Cardiovascular Risk Factor
Interventions
Vitamin D and magnesium, Vitamin D, Placebo
Dietary Supplement
Lead sponsor
Drexel University
Other
Eligibility
30 Years to 70 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Oct 19, 2026, 4:23 PM EDT
Completed Phase 3 Interventional

Ulimorelin Study of Efficacy and Safety (ULISES 007)

NCT01285570
View directory record Official record
Conditions
Gastrointestinal Dysmotility
Interventions
Ulimorelin Intravenously (IV), 5% dextrose in water
Drug
Lead sponsor
Tranzyme, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
23
States / cities
Fountain Valley, California • Los Angeles, California • Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2012 · Synced Oct 19, 2026, 4:23 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.

NCT02117570
View directory record Official record
Conditions
Clostridium Difficile Associated Disease
Interventions
Clostridium difficile vaccine, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
12
States / cities
DeLand, Florida • Savannah, Georgia • Stockbridge, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 19, 2026, 4:23 PM EDT
Terminated Phase 2Phase 3 Interventional

Lamictal in the Treatment of Post-Herpetic Neuralgia

NCT00295776
View directory record Official record
Conditions
Neuralgia, Postherpetic
Interventions
Lamictal in the treatment of Post-Herpetic Neuralgia
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 85 Years
Timeline
Started 2005
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Oct 19, 2026, 4:23 PM EDT
Completed Phase 3 Interventional

Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy

NCT00067561
View directory record Official record
Conditions
Irritable Colon, Irritable Bowel Syndrome (IBS)
Interventions
Alosetron
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
177
States / cities
Birmingham, Alabama • Calera, Alabama • Tuscaloosa, Alabama + 149 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Oct 19, 2026, 4:23 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year.

NCT02593071
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
RSV-F Vaccine, Phosphate Buffer Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
60 Years and older
Enrollment
1,330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
10
States / cities
Redding, California • Stockbridge, Georgia • Lenexa, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated May 27, 2022 · Synced Oct 19, 2026, 4:23 PM EDT